ArticleFrontiers in public health2025

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China.

Xiongxiong Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.